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TWO CASES OF PROSTATE CANCER ASSOCIATED WITH ACUTE 
MYELOID LEUKEMIA PRESENTING AS THROMBOCYTOPENIA 
DURING ENDOCRINE THERAPY 
Hiroshi MA TSUURA and Masaki SAKURAI 
From the Department oJ Urology， Matsusaka CiりHospital
Kiminobu ARIMA 
From the Department oJ Urology， Faωlty oJ Medicine， Mie University 
Prostate is one of the most common sites of multiple primary cancer (MPC). We herein present 
two cases. of prostate cancer associated with acute myeloid leukemia (AML) presenting as 
thrombocytopenia during endocrine therapy. After a diagnosis of prostate cancer (stage D2) was 
made， our patients received endocrine treatment with fosfestrol followed by a luteinizing hormone-
releasing hormone (LH司RH)analogue and bicaltamide. Thrombocytopenia appeared 8 months and 
10 months after the initiation of endocrine therapy， respectively. Because suspensions ofbicaltamide 
resulted in further deterioration of thrombocytopenia， bone marrow aspirations were done with 
hematological examination revealing features of the M2 subtype of A恥1L. Review of MPC with 
prostate cancer in the literature suggested that the combination ofprostate cancer and AML was rare. 
(Acta Urol. Jpn. 48: 87-90， 2003) 





































8，400;μ1， Hb 11. 7 g/dl， Ht 35.3%， plt 1. 7X 103/ 
μ1，分画では myeloblastを63%認めた (Fig.2A). 
骨髄像では有核細胞数 16.7X 104/μ!で， myeloblast 
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Fig. 1. Prostatic biopsy specimen reveals ade-
nocarcinoma. (A) Case 1， (B) Case 2. 
を32.4%認め，表面マーカーは CD7，13， 33および




















Fig. 2. Leukemic cels were observed in bone 









前立腺生検にて中分化型腺癌 (Gleasonscore 4+ 3) 
が検出された (Fig.IB). 一般血液検査では WBC
4，200/μ1， Hbll.lg/dl， Ht32.1%， plt26.0XI03/ 
μ1，分画では異常は認められなかった.前立腺癌
stage D2， T3NOM2の診断にて内分泌療法を開始し























染色体検査では t(8; 21)転座が認められた.AML 
(M2)と診断され，当院内科に転科となった. BHAC 
およびidarubicinhydrocroride (IDR)の併用療法に
よる寛解導入が行われ， BHAC， VP-16， DNRと
aclarubicin hydrochloride (ACR)などの多剤併用に
よる地固め療法が行われた.化学療法に加えて， LH-



























安全性情報 (Pharmaceuticalsand Medical Devices 




癌性が示唆される IARC(International Agency for 
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